Variables included in the final model were T and N category, age, performance status, and total tumor dose.
The model has an area under the curve (AUC) of 0.66 on the external validation set and an AUC of 0.62 on a 5-fold cross validation.
The Maastro clinic cohort data are publicly available at https:// and the developed models can be found at This publication was supported by the Dutch national program COMMIT (Prana Data project).A prognostic model should not enter clinical practice unless it has been demonstrated that it performs a useful role.This work was supported by the Interreg grant euro CAT and the Dutch Technology Foundation STW (Du CAT, grant No. P14-19), which is the applied science division of Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO); the Technology Programme of the Ministry of Economic Affairs; and a Manchester Cancer Research UK major center grant.Financial support was also provided by the following: EU Seventh Framework program (ARTFORCE, grant No. 601826), CTMM-Tra IT, EUROSTARS (Cloud Atlas), Kankeronderzoekfonds Limburg from the Health Foundation Limburg, Alpe d' Hu Zes-KWF (DESIGN), Dutch Cancer Society, NIH P01 CA059827, European Program H2020-2015-17 (Immuno SABR, grant No.